Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600211's PB Ratio is ranked worse than 70.9% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.9
vs SHSE:600211: 3.25
During the past 12 months, Tibet Rhodiola Pharmaceutical Holding Co's average Book Value Per Share Growth Rate was -4.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 8.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 9.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 17.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Tibet Rhodiola Pharmaceutical Holding Co was 60.00% per year. The lowest was -8.80% per year. And the median was 7.45% per year.
Back to Basics: PB Ratio
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Tibet Rhodiola Pharmaceutical Holding Co PB Ratio Related Terms
Tibet Rhodiola Pharmaceutical Holding Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tibet Rhodiola Pharmaceutical Holding Co PB Ratio Chart
Tibet Rhodiola Pharmaceutical Holding Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Rhodiola Pharmaceutical Holding Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tibet Rhodiola Pharmaceutical Holding Co PB Ratio vs Drug Manufacturers Industry
Tibet Rhodiola Pharmaceutical Holding Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) has a PB Ratio of 3.25 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. This is near median its historical median of 3.48. Over the past decade, Tibet Rhodiola Pharmaceutical Holding Co's PB Ratio has ranged from 2.06 to 15.49. According to the industry distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #653 out of 921 companies in the Drug Manufacturers industry, placing it in the top 70.9%.
Is Tibet Rhodiola Pharmaceutical Holding Co's PB Ratio too high?
Tibet Rhodiola Pharmaceutical Holding Co's current PB Ratio of 3.25 is near median its 10-year median of 3.48. Over the past 10 years, this metric has ranged from a low of 2.06 to a high of 15.49. The Drug Manufacturers industry median PB Ratio is 1.90. Tibet Rhodiola Pharmaceutical Holding Co's value of 3.25 is 71.1% above this industry median. Based on the distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #653 out of 921 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Tibet Rhodiola Pharmaceutical Holding Co has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tibet Rhodiola Pharmaceutical Holding Co's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #653 out of 921 companies for PB Ratio. This places Tibet Rhodiola Pharmaceutical Holding Co in the lower half of its industry. The industry median PB Ratio is 1.90. Tibet Rhodiola Pharmaceutical Holding Co's value of 3.25 is 71.1% above this benchmark. Historically, Tibet Rhodiola Pharmaceutical Holding Co's own PB Ratio has ranged from 2.06 to 15.49 over the past decade. While the company's 10-year median is 3.48 vs. the industry median of 1.90, Tibet Rhodiola Pharmaceutical Holding Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tibet Rhodiola Pharmaceutical Holding Co's current PB Ratio of 3.25 is 71.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tibet Rhodiola Pharmaceutical Holding Co's current PB Ratio is 3.25, which is near median its own 10-year median of 3.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tibet Rhodiola Pharmaceutical Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) is currently considered Fairly Valued. The stock's GF Value™ is ¥40.53, compared to a current price of ¥39.30 — trading 3% below its estimated fair value. The current PB Ratio is 3.25, which is near median its 10-year median of 3.48 and 71.1% above the Drug Manufacturers industry median of 1.90. Tibet Rhodiola Pharmaceutical Holding Co's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211), the current PB Ratio is 3.25 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Overvalued in 2026?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co stock appears to be undervalued.
The current stock price of ¥39.30 is trading 3% below its estimated GF Value™ of ¥40.53.
GuruFocus considers Tibet Rhodiola Pharmaceutical Holding Co to be Fairly Valued.
Key valuation signals for SHSE:600211:
PB Ratio: 3.25 (near median its 10-year median of 3.48)
GF Value™: ¥40.53 vs. price of ¥39.30 (3% below fair value)
Industry Position: 71.1% above the Drug Manufacturers median (#653 of 921)
No single metric tells the full story. See the SHSE:600211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tibet Rhodiola Pharmaceutical Holding Co Business Description
Tibet Rhodiola Pharmaceutical Holding Co is a pharmaceutical company engaged in the production and sales of capsules, biological agents, granules, and coatings. The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, involving fields such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
94GF Score
Get the complete analysis for SHSE:600211
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600211 has been successfully added to your 
